Safety aspects without loss of effectiveness in the switch of patients with multiple sclerosis from the original drug glatiramer acetate copaxone-teva on the biosimilar timexon

The requested reference [9c5a66a7d4cfb5c78ab711fba8f4380a0c6779f4] no longer exists in our database. It has been replaced by the current reference: [48c6226adbc0071a3981449d659ad22c5143cb9f]

Authors
Category Primary study
JournalNevrologicheskii Zhurnal
Year 2019
This article has no abstract
Epistemonikos ID: 10ca624482f836595fa329d5815ad7e2c22283da
First added on: Mar 31, 2022